SCHEMBL3989593

SCHEMBL3989593

CCOCC1CC[N]CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12695097 0.82 CYP2D6 (0.34)
SCHEMBL131689 0.82
SCHEMBL14486633 0.82 CYP2D6 (0.34)
Ammonia Solution, Strong SCHEMBL9287 0.79
SCHEMBL3917690 0.77 ALDH1A1 (0.32)
SCHEMBL127797 0.77
SCHEMBL1064453 0.77
SCHEMBL18417196 0.75 CYP2D6 (0.31)
SCHEMBL60078 0.75 CYP1A2 (0.42)
SCHEMBL10447402 0.75 CYP1A2 (0.42)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2035372-A1 MODULATORS OF THE HISTAMINE H3-RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO Arena Pharmaceuticals, Inc. (US) 2009-03-18 EP claimed
WO-2008005338-A1 MODULATORS OF THE HISTAMINE H3-RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO ARENA PHARMACEUTICALS, INC. (US) 2008-01-10 WO claimed